Glenmark filed the product for a clinical trial with Indias drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trial on mild to moderate COVID-19 patients.
from India Infoline News Service https://ift.tt/2YkzlTR
No comments:
Post a Comment